AbbVie's Botox Cosmetic has cleared another regulatory hurdle in its path to FDA approval for masseter prominence—the first neurotoxin indication for jawline reduction. If approved, Botox would be the first and only toxin cleared for this use, creating a new category within the aesthetic toxin market and a potential revenue stream independent of migraine, spasticity, and hyperhidrosis applications.
Regulatory
Botox Masseter Indication Moves Closer to FDA OK
AbbVie advances toward first-ever neurotoxin approval for jawline contouring.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
If approved, Botox would be the first and only neurotoxin for masseter prominence.
The masseter indication targets a growing segment of patients seeking non-surgical jawline definition, particularly in younger demographics. For practices, approval would expand the toxin conversation beyond forehead, brow, and crow's feet, adding a procedural option that complements filler and RF microneedling jawline treatments. The competitive landscape would shift: Jeuveau and other toxins would need their own sBLAs to match the indication.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.